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Background: Deletions of chromosome 10q23, including the PTEN (phosphatase and tensin homolog) locus, are
known to occur in breast cancer, but systematic analyses of its clinical relevance are lacking.
Methods: We thus analyzed a tissue microarray (TMA) with 2,197 breast cancers by fluorescence in-situ
hybridization (FISH) using a PTEN-specific probe.
Results: PTEN deletions were detected in 19 % of no special type, 9 % of lobular, 4 % of tubular cancers and 46 %
in carcinomas with medullary features. 98.7 % of deletions were heterozygous and only 1.3 % were homozygous.
PTEN deletion was significantly linked to advanced tumor stage (p = 0.0054), high-grade (p < 0.0001), high tumor
cell proliferation (Ki67 Labeling Index; p < 0.0001), and shortened overall survival (p = 0.0090). PTEN deletions were
inversely associated with features of luminal type breast cancers (ER/PR positivity; p < 0.0001 each, and CCND1
amplification; p = 0.0020). PTEN deletions were also strongly linked to amplification of genes involved in the PTEN/
AKT pathway such as MYC (p = 0.0430) and HER2 (p = 0.0065). Remarkably the combined analysis of MYC, HER2, CCND1
and PTEN aberrations suggested that aberrations of multiple PTEN/AKT pathway genes have a strong additive effect on
breast cancer prognosis. While cancers with one of these aberrations behaved only marginally different from cancers
with none, disease outcome was markedly worse in cancers with two or more aberrations as compared to those with
only one aberration (p = 0.0002). In addition, the particularly poor prognosis of patients with HER2 amplification and
PTEN deletions challenges the concept of PTEN deletions interfering with trastuzumab therapy.
Conclusion: PTEN deletion occurs in a relevant fraction of breast cancers, and is linked to aggressive tumor behavior.
Reduced PTEN function cooperates with MYC and HER2 activation in conferring aggressive phenotype to cancer cells.
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Breast cancer is the most common carcinoma detected
in women, accounting for about one fifth of new cancer
cases in females [1]. Surgical removal of the cancer rep-
resents the standard of care followed by radiation and/or
adjuvant therapy in patients considered to be at particu-
lar risk for persistent local or systemic disease. Histo-
pathological parameters are of particular importance for
assessing tumor aggressiveness. This especially applies
for pathological stage (pT), histologic grade, and nodal* Correspondence: r.simon@uke.de
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these parameters are not sufficient to predict the prog-
nosis of individual patients reliably enough in all cases.
Analysis of molecular features in cancer cells bears the
potential of providing a better estimation of the progno-
sis than classical pathological parameters alone [2–4].
The PTEN gene at 10q23 encodes a lipid phosphatase
that functions as a direct antagonist of phosphatidylinositol
3-kinase and is involved in the regulation of the AKT path-
way. Inactivation of PTEN leads to constitutively activated
levels of AKT, thus promoting cell growth, proliferation,
survival and migration through multiple downstream ef-
fectors [5]. PTEN is one of the most frequently deleted
genes in various human cancer types [6], and alterations ofis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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tric cancer [7], colorectal cancer [8], non-small cell lung
cancer [9], diffuse large B-cell lymphoma [10], mesotheli-
oma [11] and prostate cancer [12].
In breast cancer - despite various earlier studies -
frequency and relevance of PTEN alterations is unclear.
The frequency of PTEN deletions or reduced expression
varies from 4 % to 63 % in the literature [13, 14]. Some
studies on 99–151 breast cancer patients have suggested
associations between PTEN inactivation and poor progno-
sis [15–17], but this could not be confirmed in other stud-
ies involving 212–670 cancers [18–20]. In addition, PTEN
deletion has been intensively discussed as a potential pre-
dictor for failure of anti-HER2 therapy [21–23].
To better understand the clinical relevance of PTEN dele-
tions in breast cancer we analyzed more then 2,100 breast
cancers with clinical follow-up data. Fluorescence in-situ
hybridization (FISH) was applied for PTEN analysis because
FISH is the gold standard for analyzing DNA copy number
changes. Moreover, to better understand the role of PTEN
deletions in cancers with HER2 amplification we analyzed a
historical cohort of cancers that was collected before anti-
HER2 treatments were routinely applied to women with
HER2 positive breast cancer. Our data show that PTEN de-
letion is tightly linked to poor disease outcome and they
suggest this also applies to the subgroup of HER2 positive
cancers not treated with trastuzumab.
Methods
Breast cancer tissue microarray
A pre-existing tissue microarray (TMA) was used for the
purpose of this study [24]. In short, one 0.6 mm core was
taken from a representative tissue block from each patient.
The tissues were distributed among 6 TMA blocks, each
containing 263 to 522 tumor samples. The TMA con-
tained in total 2,197 human breast cancer samples from
paraffin-embedded tissue specimens fixed in 4 % neutral
buffered formalin. The median patient’s age was 63 (range
26–101) years. The use of the specimens and data for re-
search purposes was approved by local laws (HmbKHG,
§12,1) and the local ethics committee (Ethics commission
Ärztekammer Hamburg, WF-049/09 and PV3652). Ac-
cording to local laws, informed consent was not required
for this study. Patient records/information was anonymized
and de-identified prior to analysis. All work has been car-
ried out in compliance with the Helsinki Declaration. Sur-
vival data were either obtained from the cancer registry of
Basel or collected from the patients attending physicians.
Raw survival data were available from 1,982 patients (713
patients with and 1,508 without event (death)). The mean
follow-up time was 63 months (range 1–176 months).
Tumor size and nodal status were obtained from the pri-
mary pathology reports. All slides from the tumors were
reviewed by specialized pathologists to define the histologicgrade according to Elston and Ellis [25] and the tumor type
according to the WHO classification (WHO 2012). Four
μm sections of the TMA blocks were transferred to an ad-
hesive coated slide system (Instrumedics Inc., Hackensack,
New Jersey) for FISH analysis. Molecular data used in this
study were available from previously published studies.
These included amplification data obtained by FISH for
HER2, CCND1, and MYC as well as expression data ob-
tained by immunohistochemistry for estrogen receptor
(ER), progesteron receptor (PR) and Ki67 [24, 26].
Fluorescence in-situ hybridization
Four micrometer TMA sections were used for fluores-
cence in-situ hybridization (FISH). For proteolytic slide
pretreatment, a commercial kit was used (paraffin pre-
treatment reagent kit; Abbott, Wiesbaden, Germany).
TMA sections were deparaffinized, air-dried, and dehy-
drated in 70 %, 85 %, and 100 % ethanol, followed by de-
naturation for 5 min at 74 °C in 70 % formamid 2x SSC
solution. The home-made FISH probe set consisted of a
spectrum-orange labeled PTEN probe (made from a
mixture of BAC RP11-380G5 and BAC RP11-813O3),
and a spectrum-green labeled commercial centromere
10 probe (#6J37-10; Abbott, Wiesbaden, Germany) as a
reference. Hybridization was performed overnight at 37 °C
in a humidified chamber. Slides were subsequently washed
and counterstained with 0.2μmol/L 4′-6-diamidino-2-
phenylindole in antifade solution. Stained slides were
manually interpreted with an epifluorescence microscope
(Axio Imager A1, Zeiss, Oberkochen, Germany), and the
predominant FISH signal numbers were recorded in each
tissue spot. Presence of fewer PTEN signals than centro-
mere 10 probe signals in at least 60 % tumor nuclei were
considered as heterozygous deletion. Complete absence of
PTEN signals in the tumor cells, but presence of centro-
mere 10 signals and PTEN signals in adjacent normal
cells, was considered homozygous deletion (Fig. 1). Tissue
spots lacking any detectable PTEN signals in all (tumor
and normal cells) or lack of any normal cells as an internal
control for successful hybridization of the FISH probe
were excluded from analysis. These thresholds were based
on our previous study analyzing PTEN deletions on a
prostate cancer TMA [12].
Statistics
Statistical calculations were performed with JMP 9 soft-
ware (SAS Institute Inc., NC, USA). Contingency table
analysis and Chi square test were used to study the rela-
tionship between IHC and FISH results and clinicopath-
ological variables. Kaplan–Meier plots were used to
estimate disease-specific and overall survival and the
statistical significance was determined by the log rank
test. The log-Rank test was applied to test the significance
of differences between stratified survival functions.
a) b) c) 10 µm 
Fig. 1 Examples of FISH findings using the PTEN deletion probe. a Normal PTEN copy numbers as indicated by two orange PTEN signals and two green
centromere 10 signals. b Heterozygous deletion as indicated by the lack of one orange PTEN signal and two green centromere 10 signals. c Homozygous
deletion as indicated by the complete absence of orange PTEN signals and the presents of two centromere 10 signals in all tumor cells
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PTEN deletion frequency
A total of 1,239 (56.4 %) of arrayed cancer samples were
analyzable by FISH. PTEN deletions were found in 233
(19 %) interpretable breast cancers, including 17 % het-
erozygous and 2 % homozygous deletions.
Association to breast cancer phenotype
PTEN deletions were found in 19 % of NST cancers, 9 %
of lobular (p = 0.0036 vs NST), 35 % of papillary cancers
(p = 0.1150 vs NST) and 46 % of cancers with medullary
features (p = 0.0002 vs NST). If all cancers were jointly
analyzed, deletion of PTEN were significantly linked to
advance tumor stage (p = 0.0054), and high histopatho-
logical grade (p < 0.0001) in all cancers. These associations
held also true in the largest subset of No Special Type
(NST) cancers. In addition, PTEN deletions were strongly
linked to the subset of hormone receptor (ER/PR) negative
breast cancers: deletion was found in 43 % of ER negative
and 24 % of PR negative but only in 11 % of ER negative
and 11 % of PR positive breast cancers (p < 0.0001 each).
PTEN deletion was unrelated to presence of lymph node
metastases. All results are summarized in Table 1.
Association to amplifications of HER2, CCND1 and MYC
HER2, CCND1 and MYC amplification results were avail-
able from a previous study [24]. In total, FISH results on
both PTEN deletions and amplifications of HER2, CCND1
and MYC were available in subsets of 1,047 (HER2), 792
(MYC) and 1,149 (CCND1) cancers. There was a positive
association between PTEN deletion and amplification of
HER2 and MYC, but an inverse association to amplifica-
tion of CCND1. PTEN deletion was found in 27 % of 195
HER2 amplified cancers but in only 18 % of 852 tumors
with normal HER2 copy numbers (p = 0.0065), as well as
in 26 % of 57 MYC amplified cancers but in only 17 % of
735 tumors with normalMYC copy numbers (p = 0.0430).
In contrast, PTEN deletion was found in only 12 % of 237
CCND1 amplified cancers, but in 21 % of 912 tumors withnormal CCND1 copy numbers (p = 0.0020). These associ-
ations are shown in detail in Fig. 2.Association with cell proliferation
Data on the tumor cell proliferation, as determined by
immunohistochemical analysis of the Ki67 antigen, were
available from a previous study using the same TMA
[24]. PTEN deletions were strongly associated with a
high Ki67 labeling index (LI) if all cancers were jointly
analyzed (p < 0.0001), as well as in subsets of cancers
with identical grade (p < 0.05 each, Fig. 3a–d).Prognostic significance of PTEN deletion
Data on raw survival were available from 1,236 cancers
with interpretable PTEN FISH results. Presence of PTEN
deletion was linked to shortened overall survival if all
cancers were jointly analyzed (p = 0.0090, Fig. 4a), as
well as in the subsets of NST cancers (p = 0.0629,
Fig. 4b), and in the subset of NST cancers with nodal
metastases (p < 0.0001, Fig. 4c). To study, whether
PTEN deletion has an additional prognostic value in
cancers harboring co-amplification of HER2, MYC, or
CCND1, we stratified cancers for survival analysis ac-
cording to the status of PTEN and HER2 (Fig. 5a), PTEN
and MYC (Fig. 5b), as well as PTEN and CCND1
(Fig. 5c). These analyses suggested an inferior prognosis in
cancers harboring PTEN deletions with co-amplifications
of HER2, MYC, or CCND1 as compared to those without
co-amplification, but the differences did not reach statis-
tical significance. Since the failure to find significant differ-
ences was most likely due to small numbers in the various
subsets, we combined all cancers according to the number
of alterations, including PTEN deletion and amplification
of any of HER2, MYC, and CCND1. In this combined
analysis, we found a shortened survival for patients with
cancers harboring alterations in 2 or more of these genes
as compared to tumors with no or one alteration (p =
0.0002, Fig. 5d).
Fig. 2 Associations between PTEN deletion and amplifications of HER2, MYC and CCND1 analyzed by FISH
Table 1 Clinico-pathological association of PTEN deletion
PTEN FISH
Analyzable (n) normal deletion P value
All cancers 1239 81 % 19 %
Histology No special type 917 81 % 19 % -
Lobular carcinoma 123 91 % 9 % 0.005*
Cribriform carcinoma 43 88 % 12 % 0.32
Medullary carcinoma 39 54 % 46 % 0.0001
Tubular carcinoma 28 96 % 4 % 0.04
Papillary carcinoma 17 65 % 35 % 0.11
Mucinous carcinoma 29 97 % 3 % 0.03
Other rare typesa 43 58 % 42 % 0.007
pT stage pT1 411 87 % 13 % 0.005
pT2 613 78 % 22 %
pT3 61 77 % 23 %
pT4 146 79 % 21 %
BRE grade Grade 1 308 93 % 7 % <0.0001
Grade 2 472 87 % 13 %
Grade 3 457 68 % 32 %
Nodal stage pN0 524 82 % 18 % 0.18
pN1 446 79 % 21 %
pN2 64 72 % 28 %
ER status Negative 296 57 % 43 % <0.0001
Positive 906 89 % 11 %
PR status Negative 744 76 % 24 % <0.0001
Positive 408 89 % 11 %
Abbreviations: pT Pathological tumor, BRE Breast cancer histologic, ER Estrogen receptor, PR Progesterone receptor, FISH Fluorescence in-situ hybridization
a: Including adenoid-cystic carcinoma, apocrine carcinoma, atypical medullary carcinoma, carcinosarcoma, clear cell carcinoma, histiocytic carcinoma, lipid rich
carcinoma, lipid rich or histiocytic carcinoma, metaplastic carcinoma, neuroendocrine carcinoma, signet ring carcinoma, and small cell carcinoma
*: Versus cancers of no special type




Fig. 3 Association between PTEN deletion and Ki67-labeling index. a all cancers, b Grade 1 cancers, c Grade 2 cancers and d Grade 3 cancers
Lebok et al. BMC Cancer  (2015) 15:963 Page 5 of 10Discussion
Analyzing more than 1,200 informative breast cancers
using a FISH probe directed against the known tumor
suppressor gene PTEN at 10q23, we found that PTEN
deletion is strongly linked to poor patient prognosis.
PTEN deletion was found in 18.8 % of breast cancers.
These results are in the range of two earlier studies
reporting PTEN deletions in 12 %–19 % of unselected
breast cancers using FISH [27] or array CGH [16]. In
our study, PTEN deletion was defined as “fewer PTEN
signals than centromere 10 signals in at least 60 % of all
tumor cells”. These stringent criteria resulted in a 100 %
concordance of results found by FISH and comparative
genomic hybridization in a previous PTEN study of our
group in prostate cancer [12]. A higher PTEN deletion
rate by FISH (41 %) was only reported from a study on
199 highly selected metastatic breast cancers [28], as
well as from heterozygosity (LOH) studies, reporting
PTEN deletion in 30 %–41 % of 22–105 analyzed breast
cancers [29–33]. LOH induced by unequal allele distri-
bution in the case of triploid or aneuploidy cancers or
tumors with overrepresentation of chromosome 10 may
contribute to the relatively high rates of PTEN losses in
these studies. FISH represents the gold standard for gene
copy number analysis, because FISH is independent ofthe purity of cancer tissue and chromosomal aberrations
such as polysomy. Deletions can be analyzed on a cell-
by-cell basis, and abnormalities can be detected in a few
cells or even a single cell.
Numerous studies measured alterations of PTEN protein
expression by IHC in breast cancer. These studies show
highly discordant results, with PTEN loss ranging from 4
%–63 % in 33–670 analyzed breast cancers [13, 14, 18, 31].
Reasons for this variability might include inherent issues of
IHC, as no validated antibody, threshold, or protocol is
available yet for PTEN expression analysis by immunohis-
tochemistry on FFPE tissue [34]. In a previous study, we
tested a series of seven anti-PTEN antibodies, but found all
of them unsuitable for reliable measurement of PTEN ex-
pression in formalin fixed prostate cancer tissues since no
meaningful association was found between the staining
level of these antibodies and presence of PTEN deletions or
tumor phenotype [12]. Discordant results were also re-
ported for RNA expression analysis by RT-PCR. Here stud-
ies reported loss of PTEN expression in 20 % of 135 and 77
% of 59 analyzed breast cancers [16, 27]. These discrepan-
cies are not surprising, given that the results of such studies
are substantially dependent on the purity of cancer tissue
and the PTEN expression levels in normal breast epithe-
lium, as well as in inflammatory or stromal cells.
ab
c
Fig. 4 Association between PTEN deletion and patient survival.
Kaplan Meier plots showing overall (raw) survival in a all cancers
(n = 1,246), b no specific type cancers (n = 915) and c no specific
type and pN positive cancers (n = 404)
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breast cancer subtypes. Lobular cancers had a particu-
larly low and cancers with medullary features had a
markedly high rate of PTEN deletions as compared to
NST cancers. This is a novel and unexpected observa-
tion, given that gene mutations of PTEN had been re-
ported at similar rates in lobular (2 %) [35] and NST
(2.3 %) carcinomas [36]. The high rate of PTEN dele-
tions in cancers with medullary features fits well to theincreased proliferation rate, which is one of the hall-
marks of this kind of tumor [37]. However, it has been
suggested that the favorable clinical course of cancers
with medullary features may be strongly driven by a
lower tendency for lymphovascular invasion and an acti-
vated immune defense that might overrule adverse gen-
etic features [38, 39].
The data of our study show, that – at least in the lar-
gest subgroups of NST carcinomas -PTEN deletions are
strongly linked to features of unfavorable tumor pheno-
type and to shortened overall survival. While most of
the earlier studies on 22–258 breast cancers had also
found associations with at least some phenotypic fea-
tures of aggressive cancer [15–17, 30–33, 40], data were
more conflicting with respect to patient outcome. The
vast majority of studies analyzed the prognostic impact
of PTEN alterations in NST cancers by immunohisto-
chemistry [15–20, 41–43]. Half of these studies sug-
gested a prognostic impact of lost or decreased PTEN
expression in 99–182 tumors using overall survival, me-
tastasis free-survival, disease-related death or recurrence-
free survival as clinical endpoints [15–17, 43]. Other
studies could not confirm a significant association be-
tween PTEN alterations and patient outcome using these
clinical endpoints in 97–670 patients [18–20, 41, 42]. Only
one study analyzed PTEN deletions by FISH in a set of
135 tumors [16]. In line with our analysis, this study re-
vealed a strong link between PTEN deletion and reduced
metastasis-free interval. Therefore our findings, in com-
bination with the ease of measuring PTEN deletions by
next generation sequencing methods, strongly prompt for
including PTEN deletion measurement in future multi-
parametrical tests.
PTEN deletions were strongly linked to HER2 and
MYC gene amplification in our patient set. Both HER2
and MYC are closely connected to AKT/PTEN signaling.
MYC is a downstream effector of AKT-depended growth
signaling but also controls AKT pathway activity in a
negative feedback loop by up-regulation of PTEN [44].
Obviously, impairment of this control loop by deletion
of PTEN can be expected to provide a growth advantage
to cancer cells beyond MYC amplification alone. HER2
is one of the receptor tyrosine kinases upstream of
PTEN. Since HER2 amplification strongly activates AKT
signaling [45], the additional deletion of PTEN might
confer a similar growth advantage to HER2 amplified
cells as to MYC-amplified cells. In line with this notion,
we found at least a strong trend towards an inferior
prognosis for HER2 and/or MYC-amplified cancers with
co-deletion of PTEN as compared to tumors harboring
only one of these alterations.
Further in line with an important functional inter-
action between PTEN and HER2, it has been suggested




Fig. 5 Association between patient survival and co-alterations: Kaplan Meier plots showing overall (raw) survival in cancers with alterations of
a PTEN and HER2, b PTEN and MYC, c PTEN and CCND1, and d PTEN, HER2, MYC or CCND1. No alteration: neither PTEN deletion nor oncogene amplification,
PTEN deletion only: deletion of PTEN but no oncogene amplification, oncogene amplification only: oncogene amplification but no PTEN deletion, PTEN
deletion and oncogene amplification: concurrent alteration of both loci
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that studies analyzing the impact of PTEN loss on trastu-
zumab response reported massively conflicting results
[46], PTEN analysis has not been established as a clinical
routine test prior to administration of trastuzumab. Some
studies have suggested, that PTEN loss or reduced PTEN
expression is sufficient to cause a decreased response to
trastuzumab [47–49], whereas other studies found that an
additional PIK3 mutation is required to confer resistance
to anti-HER2 treatment [50, 51]. Additional studies did
not find a relationship between PTEN alterations and sen-
sitivity to trastuzumab [51, 52].
Whether or not PTEN alterations are of relevance for
response to anti-HER2 therapies is of utmost relevance.
Since PTEN deletion is found in a subset of 27 % of
HER2 amplified cancers that are eligible for HER2 treat-
ment, it can be estimated that PTEN deletion could po-
tentially account for therapy failure in about one quarter
of breast cancer patients receiving HER2 inhibitors. It is
of note, however, that the generally poor prognosis of
patients with the combination of both PTEN deletionand HER2 amplification as determined in a historical
breast cancer patient set predating the era of anti-HER2
therapies demonstrates that the poor success of trastu-
zumab in PTEN deleted cancers may also be driven by
increased cancer aggressiveness irrespective of therapy
response.
The strong association of PTEN deletions with HER2
and MYC gene amplifications also fits well with the sug-
gested role of PTEN in maintenance of genomic stability.
PTEN is required for double strand breakage (DSB) repair
by homologous recombination [53]. Consequently, PTEN
has been termed “A new Guardian of the Genome” in ref-
erence to the crucial role of the p53 tumor suppressor for
genome integrity [54]. Since erroneous DSB repair is one
important prerequisite of DNA amplification by fusion
bridge breakage [55], it seems likely that PTEN deletion
contributes to development of gene amplification. Evi-
dence for specific factors (such as for example PTEN in-
activation) facilitating the development of genomic
instability comes also from previous studies by others and
us showing a nonrandom accumulation of amplifications
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in a subset of breast cancers that are considered to show
an “amplifier” phenotype [26, 56–59].
It is thus of note, that CCND1 amplifications were in-
versely linked to PTEN deletions in our study. This finding
provides further evidence for the existence of molecularly
distinct subsets of breast cancers, one of which may be
linked to generalized genetic instability with accumulation
of numerous genomic amplifications (including HER2 and
MYC) as well as deletions (including PTEN), and another
one that might develop CCND1 amplification by a more
targeted mechanism. This noting is supported by the fact
that CCND1 amplification is strongly linked to hormone
receptor (ER/PR) positive breast cancers [60], while HER2
and/or MYC (like PTEN deletions in our study) are more
often found in ER-negative than in ER-positive cancers
[26, 61]. Such a putative instability-independent amplifica-
tion mechanism may be driven by the synergistic actions
of ER signaling and CCND1 in promoting cell cycle pro-
gression [62–64], and may include specific selection of
cells with increased CCND1 copy numbers.
The results of our study demonstrate a marked impact
of the deletion of one PTEN allele on breast cancer ag-
gressiveness and prognosis. This finding is in line with
several in-vivo studies demonstrating that deletion of
one PTEN allele is sufficient to have substantial impact
on cell biology. For example in mouse models, hetero-
zygosity for PTEN leads to massively increased suscepti-
bility to multiple tumor types [65–67], increased cell
proliferation in the thyroid and prostate gland [65], and
has been shown to cooperate with other genetic events,
such as ERG fusion in murine prostate cancer [68, 69].
In an earlier study of 2,266 prostate cancers we had been
able to demonstrate that no clinical difference existed
between 225 patients with biallelic and 152 patients with
monoallelic deletion of PTEN [12]. It was traditionally
thought that chromosomal deletion is a mechanism to
inactivate tumor suppressor genes in a two hit model for
example in combination with a mutation of the other al-
lele. However, large scale next generation sequencing of
breast cancer genomes is increasingly demonstrating
that mutations of “classical” tumor suppressor genes do
often not accompany large deletions, suggesting that
large deletions may not only serve for inactivation of a
single gene [70]. Increasing evidence suggests that dele-
tions impact affected cells by reduced dosage of multiple
different genes residing on a certain chromosomal area.
Studies in prostate cancer have demonstrated that vari-
ous chromosomal deletions have marked prognostic
relevance [12, 71–74]. As deletions are particularly fre-
quent in breast cancer, it will be interesting to evaluate
their clinical potential. This is all the more true, as dele-
tions can relatively easy be studied by NGS even from
formalin fixed material [75].Conclusions
Our data identify PTEN deletions as a frequent event in
breast cancer with marked prognostic impact. Given the
strong association with HER2 amplification, and the pu-
tative role of PTEN inactivation for HER2 therapy fail-
ure, our findings prompt for further analysis to estimate
the predictive value of PTEN deletion analysis for HER2
treatment success in breast cancer.
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